Table 3.
Clinical characteristics of patients with SMNs in the TCCSG L04-16 cohort
| TCCSG n | Primary cancer subtype | Primary risk | Day-8 risk | SMN subtype | NUDT15 genotype* |
|---|---|---|---|---|---|
| 404 | BCP-ALL | HR | HR | AML | HT |
| 105 | BCP-ALL | HR | HR | AML | WT |
| 014-008 | BCP-ALL | SR | SR | AML | WT |
| 0616084 | BCP-ALL | HR | HR | AML | HT |
| 0616086 | BCP-ALL | HR | HR-SCT | OS | HT |
| 568 | BCP-ALL | SR | SR | MDS | WT |
BCP-ALL, B-cell precursor ALL; HR, high risk; HR-SCT, high-risk stem cell transplantation; HT, heterozygous type; MDS, myelodysplastic syndrome; OS, osteosarcoma; SR, standard risk; WT, wild type.
*
HT indicates heterozygous for rs116855232.